Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Conformational States of Human Rat Sarcoma (Ras) Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis*
- M. Spoerner, Constantin Hozsa, +4 authors H. R. Kalbitzer
- Chemistry, Medicine
- The Journal of Biological Chemistry
- 11 October 2010
The guanine nucleotide-binding protein Ras exists in solution in two different conformational states when complexed with different GTP analogs such as GppNHp or GppCH2p. State 1 has only a very low… Expand
The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients…
- C. Griffiths, D. Thaçi, +9 authors M. Afonso
- Medicine
- The British journal of dermatology
- 1 April 2017
GP2015 is a proposed etanercept biosimilar.
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
- O. von Richter, Lena Lemke, +7 authors J. Jauch-Lembach
- Medicine
- Expert opinion on biological therapy
- 30 January 2019
ABSTRACT Background: To compare the pharmacokinetics of Sandoz biosimilar adalimumab (GP2017) with reference adalimumab (Humira) in healthy volunteers (PK similarity study) and to compare the… Expand
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
- O. von Richter, A. Skerjanec, +8 authors G. Wuerth
- Medicine
- British journal of clinical pharmacology
- 16 December 2016
AIMS To assess pharmacokinetics (PK) and safety of GP2015, a proposed etanercept biosimilar, in two studies: comparison with etanercept originator (ETN, bioequivalence study) and comparison of GP2015… Expand
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the…
- M. Matucci-Cerinic, Y. Allanore, +8 authors A. Schwebig
- Medicine
- RMD Open
- 1 November 2018
Objectives To demonstrate the equivalent efficacy and compare the safety and immunogenicity of an etanercept biosimilar, GP2015, with reference etanercept (ETN) in patients with moderate-to-severe,… Expand
THU0145 Pharmacokinetics and Safety of GP2015, A Proposed Etanercept Biosimilar, and Etanercept Originator Product in Healthy Male Subjects: A Randomised Two-Way Crossover Study
- M. Afonso, S. Sanguino Heinrich, J. Poetzl, H. Woehling
- Medicine
- 1 June 2016
Background GP2015 is a proposed etanercept (tumor necrosis factor inhibitor) biosimilar. Objectives To compare the pharmacokinetics (PK) and safety of GP2015 and etanercept originator product… Expand
AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®
- U. Kronthaler, M. Baron, J. Poetzl, A. da Silva
- Medicine
- 1 June 2014
Background TNFα inhibitors are highly effective drugs for the treatment of inflammatory disorders such as rheumatoid arthritis. Biosimilars are approved biologics with comparable quality, safety and… Expand
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
- J. Smolen, S. Cohen, +8 authors Dmitrij Kollins
- Medicine
- Rheumatology
- 23 July 2020
OBJECTIVES
This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with reference… Expand